These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 12743148

  • 1. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P.
    J Clin Oncol; 2003 May 15; 21(10):1952-60. PubMed ID: 12743148
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 15; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 3. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
    Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S.
    Saudi Med J; 2005 Aug 15; 26(8):1190-6. PubMed ID: 16127511
    [Abstract] [Full Text] [Related]

  • 4. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA.
    Anticancer Res; 2010 Feb 15; 30(2):547-52. PubMed ID: 20332468
    [Abstract] [Full Text] [Related]

  • 5. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 15; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 6. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 Aug 15; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 7. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E.
    Cancer Res; 2008 Aug 01; 68(15):6260-70. PubMed ID: 18676850
    [Abstract] [Full Text] [Related]

  • 8. Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications.
    Navarro S, Giraudo P, Karseladze AI, Smirnov A, Petrovichev N, Savelov N, Alvarado-Cabrero I, Llombart-Bosch A.
    Anticancer Res; 2007 Aug 01; 27(4B):2457-63. PubMed ID: 17695539
    [Abstract] [Full Text] [Related]

  • 9. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols.
    Ahmed A, Gilbert-Barness E, Lacson A.
    Pediatr Dev Pathol; 2004 Aug 01; 7(4):342-7. PubMed ID: 15383930
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K.
    Clin Cancer Res; 2001 Jun 01; 7(6):1790-7. PubMed ID: 11410521
    [Abstract] [Full Text] [Related]

  • 11. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 12. Prognostic impact of P53 status in Ewing sarcoma.
    de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindán FJ, Healey JH, Ladanyi M.
    Cancer; 2000 Aug 15; 89(4):783-92. PubMed ID: 10951341
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O.
    Anticancer Drug Des; 2000 Feb 15; 15(1):67-72. PubMed ID: 10888037
    [Abstract] [Full Text] [Related]

  • 14. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
    Gabor F, Wollmann K, Theyer G, Haberl I, Hamilton G.
    Anticancer Res; 1994 Feb 15; 14(5A):1943-50. PubMed ID: 7847832
    [Abstract] [Full Text] [Related]

  • 15. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.
    Cancer Res; 2000 Nov 01; 60(21):6160-70. PubMed ID: 11085540
    [Abstract] [Full Text] [Related]

  • 16. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.
    Cancer Res; 2002 Sep 01; 62(17):4879-83. PubMed ID: 12208734
    [Abstract] [Full Text] [Related]

  • 17. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS, Woo CW, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1673-9. PubMed ID: 12441322
    [Abstract] [Full Text] [Related]

  • 18. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E.
    Exp Oncol; 2007 Jun 20; 29(2):126-31. PubMed ID: 17704745
    [Abstract] [Full Text] [Related]

  • 19. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 20; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 20. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A, Rommel F, Breise M, Willers R, Göbel U, Wessalowski R.
    Klin Padiatr; 2002 Aug 20; 214(4):223-9. PubMed ID: 12165906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.